Royalty Pharma: Guidance Raised Again, Platform Strength Intact -- Buy Reiterated (NASDAQ:RPRX)

Core Insights - Royalty Pharma plc (NASDAQ: RPRX) has shown supportive Q3 results and made a recent investment, prompting a reiteration of a Buy rating by analysts [1]. Company Performance - The company reported strong Q3 results, which have contributed to a positive outlook for its stock [1]. Investment Strategy - Analysts emphasize a long-term, income-oriented investment approach, particularly appealing to buy-side hedge professionals [1].